Detailed Academic Paper on Cost-Effectiveness of Newborn Screening for SMA in England is Now Available
As part of its decision-making process, the UK National Screening Committee (UK NSC) considers economic modelling to be important for rare diseases, given the limitations on available evidence.
The UK SMA Newborn Screening Alliance is delighted that the UK NSC is open to considering existing economic models on the cost effectiveness of newborn screening for SMA.
SMA Alliance Chair, Laurent Servais, has worked with others on a model that evaluates the cost effectiveness of newborn screening for SMA in England and Wales, versus not introducing newborn screening for SMA.